Edwards Lifesciences (EW) said Monday that it received the CE mark for its Sapien M3 mitral valve replacement system.
The device received the CE mark designation for the transcatheter treatment of patients with symptomatic mitral regurgitation who are not suitable for surgery or transcatheter edge-to-edge therapy, according to the company.
Shares of the company were up 1% in recent trading.
Price: 70.16, Change: +0.76, Percent Change: +1.10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.